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Antiserum prepared against highly purified usual human serum cholinester- 
ase (the most common phenotype) cross-reacted identically with the atypical 
serum cholinesterase. The level o f  circulating atypical enzyme protein, 
determined immunologically, was about 30 % lower when the enzyme came 
from an atypical rather than a usual phenotype, and the level of  enzyme 
activity measured enzymatically at  Vma x with either o-nitrophenylbutyrate or 
benzoylcholine as substrate showed approximately the same degree of  
reduction. The average specific activity (activity at Vma x per microgram of  
enzyme protein) in sera from 28 usual and 20 atypical individuals did not 
differ significantly. These findings suggest that the atypical enzyme not only 
has altered catalytic properties (Km) but also might be synthesized more 
slowly, or cleared in vivo more rapidly, than the usual enzyme. 
KEY WORDS: cholinesterase; atypical cholinesterase; quantitive enzyme variation; human 
esterase. 
I N T R O D U C T I O N  
In humans,  prolonged apnea  following the admin is t ra t ion  of normal  doses of  
succinylcholine is often associated with a her i tab le  a l te ra t ion  of  serum 
chol inesterase  (EC 3.1.1.8) labeled the a typica l  phenotype.  2 A typ ica l  serum 
chol inesterase  has a h igher  apparen t  Km (a lower affinity) for choline ester 
subs t ra tes  (Davies et al., 1960), a lower affinity for inhibi tors  having a 
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quaternary nitrogen (Kalow and Davies, 1958), and a lower average rate of 
hydrolysis of benzoylcholine under standard assay conditions (0.05 mM 
benzoylcholine) (Kalow, 1965). Atypical serum cholinesterase appears to be a 
structurally modified enzyme which may differ from the usual by as little as 
one amino acid at the substrate binding site (anionic site) in the active center 
of enzyme. Although initially the proposal for an amino acid substitution was 
based upon altered kinetic properties of the enzyme (Kalow and Davies, 1958; 
Lockridge and La Du, 1978), more recently this assumption was supported by 
Muensch et al. (1978) with an electrophoretic analysis of the peptide 
fragments of the enzymes. 
The reduced rate of hydrolysis of compounds such as succinylcholine and 
benzoylcholine by atypical serum is due primarily to a decreased affinity for 
these positively charged substrates. Other factors also may contribute to a 
reduced rate of hydrolysis, for example, a decreased specific activity [hydro- 
lytic activity at saturating substrate concentration expressed as Vmax per 
microgram of enzyme protein; in the literature, specific activity has been 
called homospecific activity when the amount of protein was determined 
immunologically (Rush et al., 1974)] or a decreased level of circulating 
enzyme protein. Kalow (1965) and others (Bamford and Harris, 1964) have 
reported that the average level of serum cholinesterase activity from an 
atypical phenotype was less than that from a usual phenotype. Our laboratory 
(Lockridge and La Du, 1978) has found the enzyme from the two phenotypes 
to have the same turnover number (Vmax hydrolytic activity per active site of 
the enzyme) determined using active site-directed probes with either partially 
purified enzyme or pure cholinesterase. Yet when Rubinstein et al. (1976) 
compared the concentrations of immunologically reactive cholinesterase 
molecules present in the sera of a small number of atypical and usual 
individuals, they suggested that there were similar numbers of immunopotent 
molecules in both phenotypes. We have studied whole sera from 28 individuals 
of the usual phenotype and 20 of the atypical phenotype to characterize the 
immunological reaction of the cholinesterase phenotypes. 
MATERIALS AND METHODS 
Serum Samples 
Serum and plasma samples were obtained from normal healthy donors, from 
individuals who experienced prolonged apnea following succinylcholine 
administration, and from their relatives. The 20 individuals of atypical 
phenotype were from different pedigrees. The samples were stored at - 20°C. 
Individuals were classified as having the usual, intermediate, or atypical 
phenotype for serum cholinesterase based upon the inhibition of benzoylcho- 
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line hydrolysis by dibucaine hydrochloride (donated by CIBA Pharmaceuti- 
cals Co.) (Kalow and Genest, 1957) and sodium fluoride (Harris and 
Whittaker, 1961). Some serum samples were kindly provided by Dr. Dick 
Hoefnagel. 
Since the atypical phenotype is rare (about 1 in 2500 persons) (Harris 
and Whittaker, 1961), the 20 atypical samples designated as the representa- 
tive atypical population include virtually all of the samples classified as having 
atypical cholinesterase which were collected by our laboratory during a recent 
5-year period. Those who could be classified as CHEI*A/CHEI*S were 
excluded from the representative atypical population. The 28 usual phenotype 
samples were randomly selected from such samples collected by our labora- 
tory during the same 5-year period. Some of the usual individuals were 
obtained in the course of screening families of propositi but the effects of 
family clusters should be minimal. No atypical individuals were related and 
only three pairs of the usual individuals were related. 
Purified Serum Cholinesterase 
Usual serum cholinesterase was purified from the pooled plasma of a group of 
usual donors by the method of Lockridge and La Du (1978). The purity of the 
serum cholinesterase which was used as the enzyme protein standard was 
found to be 3.9 active sites/molecule of 34,000 daltons based upon titration 
with the fluorescent active-site probe [N-methyl-(7-dimethylcarbamoxy)qui- 
nolinium iodide] and 170 units/mg using benzoylcholine (measured under 
standard conditions which corresponds to 183/xmol/min/mg of benzoylcho- 
line hydrolyzed at Vm,x)- Polyacrylamide electrophoresis without sodium 
dodecyl sulfate (SDS) showed a single protein band and with SDS showed two 
bands, which correspond to the monomeric and dimeric forms of the enzyme 
(Lockridge et al., 1979). The micrograms of protein of pure serum cholines- 
terase was usually calculated from the absorbance at 280 nm using an 
extinction coefficient of 1.8 cm -1 for a 1.0 mg/ml solution (Lockridge and La 
Du, 1978; Lockridge et al., 1979); when very dilute protein concentrations 
were measured, the method of Bohlen et al. (1973) was used. 
Purified atypical cholinesterase was obtained from a single donor and 
prepared as described above for the usual enzyme. This preparation showed a 
banding pattern which was identical to that of the purified usual enzyme using 
polyacrylamide electrophoresis both with and without SDS. 
Enzyme  Assays  
Benzoylcholine Activity. Benzoylcholine activity was measured according to 
the method of Kalow and Lindsay (1955) using a benzoylcholine chloride 
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(Sigma) concentration of 0.05 mM in 0.067 M phosphate, pH 7.4, with a 1:100 
final dilution of serum. Measurements were made using a Gilford recording 
spectrophotometer maintained at 25°C in the sample compartment. One unit 
of enzyme catalyzes the hydrolysis of 1 #tool of substrate/min. The activity 
measured at a benzoylcholine concentration of 0.05 mM (standard conditions) 
equals 93 and 69% of the activity at saturating substrate concentrations for 
the usual and atypical cholinesterases, respectively. The fraction of the Vmax 
activity measured using standard conditions was calculated using an apparent 
K m of 0.004 mM for the usual and 0.022 mM for the atypical (Valentino et al., 
1981). The benzoylcholine activity at Vm~ was calculated from the activity 
determined under standard conditions using these factors. 
o-Nitrophenylbutyrate (ONPB) Activity. ONPB (Sigma) hydrolysis 
was measured using a method based on that of Main et al. (1961). The ONPB 
concentration was 0.66 mM in 0.067 M phosphate, pH 7.4, with a 1:300 final 
dilution of serum and a final concentration of approximately 0.17% methanol. 
A dual-beam DBG recording spectrophotometer (Beckman) maintained at 
25°C was used to measure the production of o-nitrophenol at 410 nm by 
enzymatic hydrolysis and to correct for nonenzymatic hydrolysis of the ester. 
A molar extinction coefficient of 2967 was used. ONPB was stored at -20°C 
as a stock solution of approximately 0.4 M in methanol adjusted to pH 5.0 with 
glacial acetic acid (Huggins and Lapides, 1947). The stock solution was 
diluted daily in buffer. Activity is expressed as micromoles of substrate 
hydrolyzed per minute per milliliter of serum. The Vma× ONPB activity 
equaled 164% of that measured under standard conditions for both the 
atypical and the usual phenotypes [designated #mol/min/ml at Vm~; calcu- 
lated using 0.4 mM (Valentino et al., 1981) as the Kin]. 
Immunological  Studies 
Production of  Antiserum. Rabbits wcrc immunized with two series of 
injections (Vaitukaitis et al., 1971) with approximately 40 U of usual serum 
cholincstcrase purified by thc method of Lockridgc and La Du (1978) to 150 
U/rag. The antiserum was stored at -20°C. 
Ouckterlony. Slides for Ouchterlony double diffusion were prepared 
using 1.0% Noble agar (Difco; 1 g/100 ml saline). Holes (2.5 mm in 
diameter) were cut in thc agar 6 mm from the center well using a gel punch 
(Gelman Instruments). After 2 to 3 days at room temperature precipitates 
were visualized directly or, after washing twice with phosphate-buffcrcd 
saline (PBS) (0.01 M potassium phosphatc buffer with 0.15 M NaC1, pH 7.4), 
by staining with butyrylthiocholine (Sigma) for cholinesterase activity (Juul, 
1968). 
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Immunoprecipitation. Preimmune rabbit serum and antiserum against 
cholinesterase were diluted 1:100 with PBS and then mixed together in 
various proportions. Both human serum and purified usual human cholinester- 
ase were diluted with 0.02 M phosphate buffer, pH 6.9, containing 1 mM 
EDTA, 1 mM #-mercaptoethanol, and 1 mg/ml  bovine serum albumin (BSA) 
(crystallized; Nutritional Biochemical Co.) so that the activity at Vmax was 
approximately 0.01 #mol benzoylcholine hydrolyzed/min/ml.  The diluted 
rabbit antiserum and diluted human cholinesterase were mixed 1:1, incubated 
in duplicate centrifuge tubes at 37°C for 4 hr, then at 4°C for 20 hr, and then 
centrifuged (8000g; 4°C) for 10 min in a Microfuge (Beckman). The 
supernatant was assayed for benzoylcholine activity. 
Immunoadsorption. One microliter of antiserum was mixed with either 
2.5 or 5.0 ~tl of test serum or pure cholinesterase (0.5 to 1.5 U/ml)  in a total 
volume of 0.20 ml of a PBS solution containing 0.5 mg/ml  BSA, 0.5 mM 
EDTA, and 0.5 mM/3-mercaptoethanol. Each sample was assayed in dupli- 
cate. Incubation and precipitation were described under Immunoprecipita- 
tion. Since this quantity of antiserum was in excess of that required to 
precipitate the cholinesterase in the test serum or the purified cholinesterase 
controls, the quantity of antiserum remaining in the supernatant could be 
quantitated in a second precipitation and used as a measure of the cholinester- 
ase added. Thus 0.10 ml of the supernatant was transferred to another 
centrifuge tube which already contained 0.10 ml of PBS having 0.005 U 
cholinesterase, 1 mM EDTA, 1 mM/3-mercaptoethanol, and 1 mg/ml  BSA. 
This second mixture was incubated and centrifuged as was the first. The 
benzoylcholine activity remaining in 0.10 ml of the second supernatant was 
assayed. Since various concentrations of pure cholinesterase were used in the 
first incubation, the micrograms of enzyme protein could be equated with the 
benzoylcholine activity remaining in the second supernatant. One equivalent 
microgram (E#g) of enzyme protein in a serum sample is defined as that 
which gave the same activity in the second supernatant as did 1 #g of the 
control pure cholinesterase. The Etzg/ml for each sample was determined in 
duplicate at least three times. 
Radial Immunodiffusion. Radial immunodiffusion was carried out in 
gels containing 1% agar, 0.15 M NaC1, 0.1% NAN3, 0.01% merthiolate, and 
0.16% (v/v) antiserum. Twelve milliliters of the 54°C gel was applied to a 
glass plate, 8 x 10 cm. Five microliters of serum or purified serum cholinester- 
ase was applied in duplicate to wells (1.5-mm diameter) and allowed to 
incubate at room temperature for 48 hr. Each gel was calibrated with five or 
six concentrations of pure enzyme from 0.25 to 1.5 U/ml.  The plate was 
stained for cholinesterase activity with butyrylthiocholine (Juul, 1968). The 
diameter of the stained region around each well was measured and the area 
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calculated. One equivalent microgram of cholinesterase in serum was defined 
as having the same area of  stained region as did 1 t~g of  pure serum 
cholinesterase on the same gel. The equivalent micrograms per milliliter for 
each serum sample was determined in duplicate on at least two gels. Serum 
from one "silent" phenotype individual was used as a control. 
R E S U L T S  
Qualitative Reaction of Antiserum with Cholinesterase 
Using the Ouchter lony double-diffusion technique, the antiserum prepared 
against pure usual serum cholinesterase cross-reacted with atypical serum 
cholinesterase in a reaction of  identity when the precipitates were visualized 
by staining for cholinesterase activity (Fig. 1). Another  Ouchter lony plate 
having similar reagents but visualized directly using indirect lighting also 
showed a reaction of identity between the atypical and the usual enzymes (no 
figure presented). Figure 2 illustrates that  the usual, atypical, and purified 
pooled usual sera had a similar immunoequivalence. The usual and atypical 
sera as well as the purified sample had similar immunoequivalence points and 
a similar fraction of  the total activity precipitated per unit of antiserum. 
Maximal  precipitation of over 95% of the total enzyme activity occurred in 
each case. 
Quantitation of  Serum Cholinesterase 
The quantitation of serum cholinesterase by immunodiffusion was not 
affected by other serum proteins or agents. The serum from one individual 
Fig. 1. Ouchterlony double diffusion using the anti- 
serum produced against the usual serum cholinester- 
ase shows a reaction of identity between the usual 
and the atypical cholinesterases. The antiserum was 
placed in the center well. The outer wells contained 
purified usual enzyme (well 1), purified atypical 
enzyme (wells 3 and 6), and sera from a usual 
individual (wells 2 and 5) and an atypical individual 
(well 4). After incubation for 2 days, the gel was 
washed with saline and stained for cholinesterase 
activity with butyrylthiocholine (Juul, 1968). 
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Fig. 2. The immunotitration of serum cholinester- 
ase activity was similar for whole sera from an 
atypical (O)- and a usual (A)-phenotype individual 
and a purified preparation of usual cholinesterase 
(*), which hydrolyzed 0.008, 0.011, and 0.011/zmol 
of benzoylcholine/min/ml extrapolated to saturat- 
ing substrate concentration, respectively. The quan- 
tity of rabbit serum in each precipitation was held 
constant by substituting preimmune serum for post- 
immune serum. The extrapolated equivalence points 
(as microliters of postimmune antiserum) are 0.29 
for the atypical serum, 0.36 for the usual serum, and 
0.35 for the purified usual serum cholinesterase. The 
ratio of the equivalence point to the Vma x benzoyl- 
choline activity of the sample (as microliters per 
Vma x activity) was 0.028 for the atypical serum, 
0.031 for the usual serum, and 0.031 for the purified 
usual cholinesterase. 
homozygous  for the "s i len t"  allele, when mixed with a pure  chol inesterase  
s tandard ,  did  not increase the  size of the s ta ined immunodiffusion ring. The  
silent serum had no de tec tab le  act ivi ty  with benzoylcholine.  Al though  some 
s i lent -phenotype individuals  show cross-react ing mate r ia l  (Al t l and  and 
Goedde ,  1970), this one did  not. The  quan t i ty  of enzyme protein de te rmined  
by immunodiffusion was not affected by a lkyla t ing  the enzyme in vitro with 
di isopropylf luorophosphate .  The  areas  of  the butyryl th iochol ine-s ta in ing  
regions from immunodiffusion of purified usual  and a typica l  cholinesterases 
(Fig.  3) were l inear ly  re la ted  to protein  (r  = 0.99), and the area  of s taining per 
mic rog ram of  protein was s imilar  for both types of enzyme (12.5 _+ 0.3 and 
13.8 _+ 0.4 mm2/#g  for the usual  and a typical ,  respectively).  The  equivalent  
mic rograms  per mil l i l i ter  for the nine concentra t ions  of protein from a typica l  
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Fig. 3. The areas of the butyrlthiocholine-staining ring were 
well correlated with the protein concentrations determined by 
the method of Bohlen et al. (1973). Immunodiffusion of pure 
cholinesterase from an atypical (O) and a usual (A) pheno- 
type was carried out using concentrations of enzyme similar 
to those found in whole serum. 
phenotype (with the usual phenotype as a standard) did not differ from that 
determined fluorometrically using a paired Student's t test (t = 1.38, P < 
0.20). 
There was a highly significant correlation (r = 0.77, P < 0.01) between 
the amount of enzyme protein determined using immunodiffusion and that 
determined using immunoadsorption for four atypical and seven usual sam- 
ples. Since a paired Student's t test comparing the two methods showed no 
significant difference, the values for these samples were averaged and 
additional serum samples were assayed using only immunodiffusion. 
The individual variability of serum cholinesterase concentration, mea- 
sured enzymatically and immunologically, and specific activity was minimal 
among the serum samples collected from one individual on 10 different 
occasions over the course of a period of about 1 year (Table I). Serum 
cholinesterase activity has been known to remain relatively constant in each 
individual. The standard deviation of benzoylcholine activity was equal to 
7.3% of the mean activity, which is quite similar to that of 8.4% reported by 
Wetstone and LaMotta  (1965). The concentration of enzyme protein and 
specific activity also showed little variability (6.9 and 9.9%, respectively). 
These results demonstrate the stability of these characteristics within an 
individual. 
Serum samples from 11 individuals (4 usual and 7 atypical), representing 
a wide range of serum cholinesterase activities, showed (Figs. 4A and B) a 
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highly significant correlation between either ONPB or benzoylcholine activity 
at Vmax and enzyme protein (r = 0.934, P < 0.001, and r = 0.935, P < 0.001, 
respectively). Likewise, ONPB activity was highly correlated with benzoyl- 
choline activity extrapolated to Vm~x conditions. When specific activity using 
either ONPB or benzoylcholine was plotted against enzyme activity (Fig. 4C; 
data in Fig. 4B), it became apparent that those individuals having a lower 
activity also tended to have a lower specific activity. Some individuals had a 
relatively low activity level and a low level of enzyme protein and also tended 
to have a lower specific activity, and they included both atypical and usual 
individuals, rather than exclusively atypical people. This property was not, 
then, associated with the atypical allele and may represent some environ- 
mental influence independent of the genetic factors which determine the 
atypical and usual cholinesterase characteristics. 
The amount of enzyme determined by ONPB or benzoylcholine activity 
(extrapolated to Vma x conditions) or by immunodiffusion was significantly less 
(33, 32, and 27% decrease, respectively) for the 20 atypical- versus the 28 
usual-phenotype individuals (Table II). Both groups appeared to have a 
unimodal and symmetric distribution of these characteristics (the coefficients 
of skewness, gl, at -0.406 and -0.476, were not significantly different from 
zero for the equivalent micrograms per milliliter of both the usual and the 
atypical populations, respectively). The specific activity of serum cholinester- 
ase with either ONPB or benzoylcholine as the substrate was not significantly 
different for the two phenotypes. Therefore, the decreased enzymatic activity 
of the atypical population was due to a decreased quantity of circulating 
enzyme. 
Table I. Variation of Serum Cholinesterase Level and Specific Activity 
in One Individual Sampled at Different Times = 
Coefficient of 
Property Mean _+ SD variation b (%) 
Number  of samplings 10 - -  
Benzoylcholine activity 1.14 _+ 0.083 7.29 
(~mola/min/ml at Vmax) c 
E t tg/ml 7.24 _+ 0.48 6.58 
Sp act" 0.159 _+ 0.014 8.96 
aBlood was drawn at 10 different times at least 1 week apart  over a l-year period. 
bThe coefficient of variation is equal to the standard deviation expressed as a percentage of the 
mean. 
CBenzoylcholine activity was measured under standard conditions and adjusted to that at 
saturating substrate concentration. 
dEtLg/ml was determined by immunodiffusion using purified usual cholinesterase as a standard. 
eSpecific activity is the ratio of activity at saturating substrate concentration (here benzoylchol- 
ine activity) to Epg/ml.  
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Fig. 4. The relationship of serum cholinesterase level deter- 
mined by immunodiffusion to serum cholinesterase activity 
using ONPB (A) or benzoycholine (B) as substrate. The 
relationship of specific activity using benzoycholine to 
equivalent micrograms of enzyme protein is presented in C. 
Four usual (A) and seven atypical (o) serum samples were 
selected to represent a wide range of cholinesterase activi- 
ties per milliliter of serum. 
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Table ii. Comparison of the Atypical Versus the Usual Serum Samples 
Phenotype 
Usual Atypical Percentage 
Property (mean -- SD) (mean _+ SD) difference ~ p~ 
103 
N 28 20 
ONPB activity 
/zmol/min/ml 2.92 _+ 0.71 1.96 ± 0.56 - 3 3  <0.001 
/~mol/min/ml at Vmax b 4.80 --+ 1.19 3.21 --+ 0.95 --33 <0.001 
Benzoylcholine activity 
U/ml  0.826 _+ 0.205 0.418 _+ 0.114 -51  <0.001 
#mol/min/ml  at Vmax c 0.892 --+ 0.225 0.606 --+ 0.171 --32 <0.001 
E # g / m l ' a  6.32 _+ 1.46 4.55 _+ 1.19 --27 <0.001 
Sp act e 
Benzoylcholine substrate 0.142 x 0.024 0.135 _+ 0.027 - 3  NS 
ONPB substrate 0.756 x 0.114 0.704 _+ 0.120 - 8  NS 
apercentage difference = 100% x (values for the atypical - the usual)/usual. The P value was 
determined by a Student t test. 
bONPB activity extrapolated to saturating substrate concentration equals 164% of the standard 
activity for both the usual and the atypical. 
c See Table I, footnote c. 
aSee Table I, footnote d. 
eSee Table I, footnote e. 
DISCUSSION 
We have compared the quantitative and qualitative reaction of atypical and 
usual cholinesterases with an antiserum made using pure usual enzyme. 
Qualitatively the antiserum reacted in a similar manner with the usual and 
atypical enzymes using both double diffusion and immunoprecipitation. 
Quantitatively the reaction of the antiserum with the purified usual and 
atypical enzymes was similar as measured by immunodiffusion. The equiva- 
lent micrograms of purified atypical enzyme was not significantly different 
from that determined by protein determination. Thus, the serum cholinester- 
ase from the usual and atypical phenotypes could be quantitated using this 
antiserum, as both forms of the enzyme reacted identically (qualitatively and 
quantitatively) with the antiserum. 
We found that the average concentration of enzyme protein and the level 
of enzyme activity at Vmax in the serum from the representation atypical group 
were lower than those from the usual group, but the average specific activities 
for each phenotype were very similar. While the atypical allele has been 
associated historically with an increased Kin, now we have found it to be 
associated also with a reduced level of circulating enzyme protein (a quantita- 
tive reduction). The relatively small decrease (27%) in the average enzyme 
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level in sera from the atypical phenotypes should have little additional effect 
on the metabolism of choline esters such as succinylcholine; the apparent Km 
for succinylcholine is sufficiently high to preclude hydrolysis by the atypical 
enzyme in vivo (Kalow and Gunn, 1957; Goedde et al., 1968). However, the 
rate of hydrolysis of some drug esters having nearly the same apparent Km for 
both the atypical and the usual enzymes might show a lower rate of hydrolysis 
or a modified pattern of tissue distribution because of the lower atypical 
enzyme protein concentration. For the model substrate o-nitrophenylbutrate, 
which has a similar Km with both phenotypes, there was a decreased rate of 
hydrolysis in vitro in proportion to the decrease in atypical enzyme protein. It 
remains to be determined whether the quantitative difference would have a 
significant effect on the hydrolysis or tissue distribution of heroin (Lockridge 
et al., 1980) and aspirin (Hofstee, 1951; Valentino et al., 1981), which are 
hydrolyzed by cholinesterase. 
The decreased level of circulating enzyme protein found for individuals 
of atypical phenotype (27%) is similar to the decrease in enzymatic activity 
(23%) found by Bamford and Harris (1964) when they compared the Vmax of 
a-naphthylacetate activity of serum cholinesterase from 10 usual- versus 9 
atypical-phenotype individuals. Under standard assay conditions (not Vmax 
conditions) for benzoylcholine hydrolysis by serum cholinesterase, the average 
activity of our atypical samples was 51% of those from the usual phenotype, 
which is in good agreement with the 50% reported by Kalow (1965). 
Rubinstein et al. (1976) suggested that the atypical and usual phenotypes 
have a similar concentration of immunopotent molecules. Yet the results of 
Rubinstein et al. (1978; their Fig. 5) appear to support our finding of a smaller 
amount of enzyme in atypical sera. These differences were minimized, 
however, because the studies were directed toward the unusual features of the 
CHEI*J and CHE1 *K variants. 
Our finding that the atypical and usual enzymes had similar specific 
activities supports the hypothesis previously presented that neither the turn- 
over number of the hydrolytic site [(Lockridge and La Du, 1978) esteratic site 
of Wilson and Bergmann (1950)] nor the number of catalytic sites per 
tetrameric enzyme molecule (Lockridge and La Du, 1978) is altered in the 
atypical phenotype. 
The specific activity of cholinesterase from some usual and atypical 
individuals was decreased. It is possible that the individuals having a reduced 
specific activity are variants of cholinesterase similar to those identified by 
Rubinstein et al. (1976, 1978), but the variants which they identified were all 
of usual dibucaine number and the variants appeared to be rare. Possibly other 
variants at the CHE1 and/or other loci affect the specific activity of serum 
cholinesterase. Since sera from some individuals homozoygous for the "silent" 
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allele have very little or no activity with virtually normal levels of cross- 
reacting material (Altland and Goedde, 1970; Goedde et al., 1965; Goedde 
and Altland, 1968; Rubinstein et al., 1970; Lubin et al., 1973), it is possible 
that some individuals in our study populations could have been heterozygous 
for the silent allele. This is unlikely because the frequency of the silent allele is 
extremely low [heterozygotes occurring at an estimated frequency of about 
1:167  (Simpson and Kalow, 1964)]. Certainly, environmental factors acting 
in vivo such as exposure to pesticides or in vitro changes such as partial 
denaturation while stored frozen could be the cause of the decreased specific 
activity in some samples. Family studies will be needed to establish the degree 
to which hereditary and environmental factors determine the variability in 
specific activity observed in these selected samples. 
The decreased average level of circulating cholinesterase in the serum of 
the atypical population might be caused by a number of genetic factors. If a 
significant fraction of our atypical phenotype population were heterozygous 
for the silent allele, the average level of circulating cholinesterase might be 
lowered and show a bimodal distribution. Our sample population of atypical 
individuals did not appear bimodal and any individuals classified as 
C H E I * A / C H E I * S  (based upon parental or more extensive pedigree analy- 
sis) were excluded from our atypical group. Thus, the 27% decrease in the 
average level of enzyme in the atypical group is unlikely to be caused by a 
significant number of individuals heterozygous for the silent and atypical 
alleles. No rare quantitative variants of atypical serum cholinesterase have 
been described in the literature which would lower the level of circulating 
enzyme. There are some rare alleles reported in the literature which appear to 
be variants of the usual allele (usual dibucaine number), CHEI*J,  CHEI*K 
(Rubinstein et al., 1976, 1978; Garry et al., 1976), and CHEI*NFLD 
(Simpson and Elliott, 1981). The Cynthiana variant and the C ~÷ traits are 
both associated with higher levels of cholinesterase activity, but neither of 
these traits would offer a logical explanation for the observed difference 
between the usual and the atypical populations. The CHE2*C 5÷ variant of 
cholinesterase segregates at a separate locus, the CHE2 locus (Harris et al., 
1963) and the Cynthiana variant of serum cholinesterase is extremely rare 
(Neitlich, 1966; Yoshida and Motulsky, 1969). Therefore, none of these other 
alleles affecting serum cholinesterase activity is likely to account for the 
difference between our atypical and our usual phenotype groups. It seems 
more likely that there is a direct effect of the usual versus the atypical alleles 
or a closely linked allele. 
The decreased circulating quantity of atypical enzyme protein could be 
accounted for by a decreased rate of synthesis or, more likely, by an increased 
rate of clearance from the blood. Serum cholinesterase is a sialo-glycoprotein 
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(Svensmark, 1961) having about 72 sialic acid residues per monomer  (calcu- 
lated from Haupt  et al., 1966). The clearance of  other serum glycoproteins 
such as ceruloplasmin appears to be determined by the removal of  sialic acid 
exposing terminal galactose moieties (Ashwell and Morrell, 1974). Some 
evidence exists suggesting that  the net surface charge of the atypical enzyme 
is less than the usual. Liddell et al. (1962) have reported that  the atypical 
enzyme is less tightly bound to the anion-exchange resin DEAE-cellulose. The 
isoelectric point of  atypical enzyme (4.20) also differs from the usual [3.99 
(Das, 1974)]. Since the net surface charge is likely to be determined 
predominantly by sialic acid, the decreased net surface charge of  the atypical 
enzyme may be an indication of  a decreased sialic acid content and an 
increased tendency for clearance from the serum. I f  such a difference exists, it 
has not been detected by in vi tro heat stability studies (Kalow, 1962). 
Measuring specific activity in a usual population with these techniques 
would be of theoretical interest as a means of  detecting new alleles (Rubin- 
stein et al., 1976, 1978). It would also be of  practical interest in identifying 
individuals exposed to, and recovering from exposure to, environmental toxins, 
such as organophosphate insecticides. Specific activity might  be a more 
reliable measure of  exposure and recovery than following the postexposure 
activity levels only. 
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